Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ultrasensitive Graphene Biosensors Detect Cancer Risk Biomarker

By Doris Mendieta, Contributing News Editor
Posted on 05 Oct 2014
An ultrasensitive biosensor utilizing the exceptional electronic and thermal properties of graphene has been used to detect molecules that indicate an increased risk of developing cancer.

The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.

Bioengineers the University of Swansea (UK) developed a viable biosensor by putting graphene onto a silicon carbide substrate under extremely high temperatures and low pressure to form the basis of the biosensor. More...
They patterned graphene devices, using semiconductor processing techniques, before attaching a number of bioreceptor molecules to the graphene devices. These receptors were able to bind to, or target, a specific molecule present in blood, saliva or urine.

The molecule, 8-hydroxydeoxyguanosine (8-OHdG), is produced when DNA is damaged and, in elevated levels, has been linked to an increased risk of developing several cancers. The team used X-ray photoelectron spectroscopy (VG Scienta; Pleasanton, CA, USA) and Raman spectroscopy (Renishaw, Illinois, IL, USA) to confirm that the bioreceptor molecules had attached to the graphene biosensor once fabricated, and then exposed the biosensor to a range of concentrations of 8-OHdG. When 8-OHdG attached to the bioreceptor molecules on the sensor, there was a notable difference in the graphene channel resistance, which the scientists were able to record.

The graphene sensor was capable of detecting 8-OHdG concentrations as low as 0.1 ng/mL which is almost five times more sensitive compared with enzyme-linked immunosorbent assays (ELISAs). The graphene biosensor was also considerably faster at detecting the target molecules, completing the analysis in a matter of minutes. The potential of the biosensor to diagnose and monitor a whole range of diseases as it is quite simple to substitute the specific receptor molecules on the graphene surface.

Owen Guy, PhD, an associate professor of engineering and coauthor of the study, said, “Graphene has superb electronic transport properties and has an intrinsically high surface-to-volume ratio, which make it an ideal material for fabricating biosensors. Now that we've created the first proof-of-concept biosensor using epitaxial graphene, we will look to investigate a range of different biomarkers associated with different diseases and conditions, as well as detecting a number of different biomarkers on the same chip.” The study was published on September 19, 2014, in the journal 2D Materials.

Related Links:

University of Swansea
VG Scienta  
Renishaw



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.